Your session is about to expire
← Back to Search
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327
Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new imaging agent called 18F-BMS-986327 in both healthy people and those with a lung disease called IPF. The agent helps doctors see how active certain receptors are in the lungs using PET scans.
Eligible Conditions
- Pulmonary fibrosis
- Healthy Subjects
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Group I: Part 3Experimental Treatment1 Intervention
Group II: Part 2Experimental Treatment1 Intervention
Group III: Part 1Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
18F-BMS-986327
2019
Completed Phase 1
~20
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,691 Previous Clinical Trials
4,097,574 Total Patients Enrolled